-
Reply to: Correspondence on ‘Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer’ J. Hepatol. (IF 26.8) Pub Date : 2025-02-12 Sohyun Hwang, Seonjeong Woo, Chan Kim, Hong Jae Chon
Section snippets Authors’ contributionsSohyun Hwang and Seonjeong Woo: Study design & Manuscript writing.Chan Kim and Hong Jae Chon: Study design & Manuscript revision. Uncited reference6.. Financial supportThis research was funded by the National Research Foundation of Korea (NRF) grants, supported by the Korean government (MSIT): grant numbers NRF-2023R1A2C2004339 to Hong Jae Chon, NRF-2023R1A2C2006375
-
Response to Zhang et al.: Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma J. Hepatol. (IF 26.8) Pub Date : 2025-02-12 Changhoon Yoo
Section snippets Authors' contributionsChanghoon Yoo: manuscript writing and final approval Financial supportNo financial support Declaration of Competing InterestCY received honoraria from Servier, Bayer, AstraZeneca, Merck Sharp & Dohme, Eisai, Roche, Celgene, Bristol Myers Squibb, Ipsen, Novartis, Boehringer Ingelheim, Boryung, Mundipharma, Autem Therapeutics, Qurient, HLB, and Elevar Therapeutics;
-
Unveiling the Molecular Legacy of Transient Insulin Resistance: Implications for Hepatic Metabolic Adaptability J. Hepatol. (IF 26.8) Pub Date : 2025-02-11 Alexandre Berthier, Céline Gheeraert, Manjula Vinod, Manuel Johanns, Loïc Guille, Joel T. Haas, Julie Dubois-Chevalier, Jérôme Eeckhoute, Bart Staels, Philippe Lefebvre
-
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway J. Hepatol. (IF 26.8) Pub Date : 2025-02-11 Zhengshuai Liu, Shuang Wei, Yang Jiang, Weitong Su, Fengguang Ma, Genxiang Cai, Yuxiao Liu, Xiaoyang Sun, Ling Lu, Wenguang Fu, Yong Xu, Ruijing Huang, Jian Li, Xu Lin, Aoyuan Cui, Mengwei Zang, Aimin Xu, Yu Li
-
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH J. Hepatol. (IF 26.8) Pub Date : 2025-02-10 Stephen A. Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, Madhavi Rudraraju, Dean Tai, Katy Wack, Amrik Shah, Robin Besuyen, Hilde H. Steineger, David.A. Fraser, Arun J. Sanyal
-
Metabolic dysfunction-associated steatotic liver disease a multisystem disease: assessing the cost effectiveness of pharmacotherapies J. Hepatol. (IF 26.8) Pub Date : 2025-02-10 Christopher D. Byrne, Gregory J. Dore
No Abstract
-
Reply to: “Optimizing Antiviral Prophylaxis Strategies: Insights and Reflections on a Real-World Study” and “Optimal Timing To Initiate Antiviral Prophylaxis of MTCT: More Required to Be Done” J. Hepatol. (IF 26.8) Pub Date : 2025-02-08 Mingwang Shen, Shihao He, Naijuan Yao, Li Xie, Lei Zhang, Tianyan Chen
Section snippets Authors' contributionsMS, LZ, TC, and SH conceived and designed the study. MS and SH analyzed the data, carried out the analysis, and performed numerical simulations. MS and SH wrote the first draft of the manuscript. MS, LZ, and TC critically revised the manuscript. All the authors contributed to writing the paper and agreed with the manuscript results and conclusions. Data availability
-
Reply to: “Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective” J. Hepatol. (IF 26.8) Pub Date : 2025-02-08 Jimmy Che-To Lai, Jie Cai, Terry Cheuk-Fung Yip
Section snippets AcknowledgementsNone. Authors' contributionsAll authors were responsible for writing the article. All authors read and approved the final version of the manuscript. Financial supportNone declared. Declaration of Competing InterestJimmy Lai has served as a speaker for Gilead Sciences and Abbott, and an advisory committee member for Gilead Sciences and Boehringer Ingelheim. Cai J declares
-
Treatment coverage of the 2024 updated WHO guidelines for patients with chronic hepatitis B J. Hepatol. (IF 26.8) Pub Date : 2025-02-08 Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Chao Wu, Rui Huang
Section snippets Authors' contributionsDr. Huang had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Concept and design: Huang, Wang, Wu.Acquisition, analysis, or interpretation of data: All authors.Drafting of the manuscript: Wang, Huang.Critical review of the manuscript for important intellectual content: Huang
-
Revealing bias in feature importance through PLS-DA: A critical examination of machine learning applications in chronic liver disease J. Hepatol. (IF 26.8) Pub Date : 2025-02-07 Yoshiyasu Takefuji
Section snippets Financial supportThe author did not receive any financial support to produce this manuscript. Conflict of interestThe author declares no conflict of interest.Please refer to the accompanying ICMJE disclosure form for further details.
-
Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m6A-regulated expression of a novel anti-fibrotic target ETV4 J. Hepatol. (IF 26.8) Pub Date : 2025-02-04 Xiaoyong Xue, Runping Liu, Yajie Cai, Liping Gong, Guifang Fan, Jianzhi Wu, Xin Li, Xiaojiaoyang Li
-
Reply to: “The HDL criterion for MetALD can misclassify patients with cirrhosis” J. Hepatol. (IF 26.8) Pub Date : 2025-02-04 David Marti-Aguado, José Luis Calleja, Ramon Bataller, Javier Crespo, María Teresa Arias-Loste
Section snippets Data availability statement (delete if not applicable)Data that support the findings of this study are available from the corresponding author upon reasonable request. AcknowledgementsD.M.A. is recipient of a Joan Rodés award (JR22/00002), Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation), and a grant Grupo de Investigación Emergente (CIGE/2022/37) from Conselleria
-
The Freiburg Index of Post-TIPS Survival (FIPS) identifies patients at risk for further decompensation and ACLF after TIPS J. Hepatol. (IF 26.8) Pub Date : 2025-02-04 Lukas Sturm, Michael Schultheiss, Fabian Stöhr, Christian Labenz, Benjamin Maasoumy, Anja Tiede, Michael Praktiknjo, Leon Louis Seifert, Timo Alexander Auer, Uli Fehrenbach, Felix Piecha, Aenne Harberts, Johannes Kluwe, Tony Bruns, Maike Rebecca Pollmanns, Johannes Chang, Jakub Grobelski, Christian Jansen, Carsten Meyer, Marlene Reincke, Dominik Bettinger
-
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies J. Hepatol. (IF 26.8) Pub Date : 2025-02-04 Homie A. Razavi, Imam Waked, Huma Qureshi, Loreta A. Kondili, Ann-Sofi Duberg, Soo Aleman, Junko Tanaka, Jeffrey V. Lazarus, Daniel Low-Beer, Zaigham Abbas, Antoine Abou Rached, Alessio Aghemo, Inka Aho, Ulus S. Akarca, Said A. Al-Busafi, Waleed K. Al-Hamoudi, Khalid Al-Naamani, Ahmed Sabry Alaama, Manahil M. Aldar, Mohammed Alghamdi, Eli Zuckerman
-
Association of Metabolic Signatures of Air Pollution with MASLD: A Note on Data Consistency J. Hepatol. (IF 26.8) Pub Date : 2025-02-03 Jianmin Zhao, Jianjun Zhao
Section snippets Authors' contributionsJianmin Zhao: conceptualization and manuscript draft.Jianjun Zhao: conceptualization, critical revision, and final approval. Financial supportNone Declaration of Competing InterestThe authors declare that they have no conflicts of interest.Please refer to the accompanying ICMJE disclosure forms for further details. AcknowledgementsThe authors have no specific
-
Response to: Unlock AI-Safe-C score's potential at all levels: Improve methods and overcome barriers J. Hepatol. (IF 26.8) Pub Date : 2025-02-03 Huapeng Lin, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
Section snippets Data availability statement (delete if not applicable)Data and results are available upon reasonable request to the corresponding author. AcknowledgementsNo acknowledgements for present study Authors' contributionsResearch design (H.L., SU.K.), data acquisition (all authors), data analysis (H.L., TC.Y.), manuscript draft (H.L., TC.Y., VW.W., SU.K.). All authors approved the final version
-
Multiomic analysis uncovers a continuous spectrum of differentiation and Wnt-MDK-driven immune evasion in hepatoblastoma J. Hepatol. (IF 26.8) Pub Date : 2025-02-01 Daniel Münter, Flavia W. de Faria, Mathis Richter, Irene Aranda-Pardos, Marc Hotfilder, Carolin Walter, Enya Paga, Clara Inserte, Thomas K. Albert, Rajanya Roy, Shariyah Rahman, Nicole C. Riedel, Volker Müller, Andreas Pascher, Karsten Wiebe, Irene Schmid, Christian Vokuhl, Beate Winkler, Eva Jüttner, Simon Vieth, Kornelius Kerl
-
Metabolic dysfunction-associated steatotic liver disease may increase intrahepatic interferon gene signatures in patients with chronic hepatitis B J. Hepatol. (IF 26.8) Pub Date : 2025-02-01 Yan Han, Jing Tang, Peng Hu, Hong Ren, Zhiwei Chen
Section snippets Authors' contributionsYan Han and Jing Tang was involved in clinical sample collection, in vivo experiment, data analysis and interpretation, drafting of the manuscript. Peng Hu and Hong Ren were involved in interpretation of data, critical revision of the manuscript and study supervision. Zhiwei Chen was involved in study concept and design, interpretation of data, drafting of the
-
MOVING DIAGNOSIS OF LIVER FIBROSIS INTO THE COMMUNITY J. Hepatol. (IF 26.8) Pub Date : 2025-01-30 Elisa Pose, Salvatore Piano, Maja Thiele, Núria Fabrellas, Emmanuel A. Tsochatzis, Pere Ginès
Chronic liver diseases (CLD) are a leading cause of death worldwide, with alcohol consumption and metabolic risk factors as the two reasons accounting for the majority of cases of CLD in many developed countries. Currently there is a lack of specific strategies for early diagnosis of CLD and consequently most cases are diagnosed in advanced stages of the disease, which is associated with negative consequences
-
Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity J. Hepatol. (IF 26.8) Pub Date : 2025-01-30 Zefan Zhang, Chenlu Geng, Minfang Song, Hengbin Liang, Kaiqian Zhou, Yang Liu, Jing Wu, Xingxu Huang, Jian Zhou, Jia Fan, David H. Peng, Liye Zhang, Yong Cang, Yunfan Sun
-
Loss or gain of function: The functional complexity of the PNPLA3 I148M Variant J. Hepatol. (IF 26.8) Pub Date : 2025-01-30 Sepideh Mikaeeli, David E. Cohen
Section snippets Conflict of interest statement:The authors have no conflicts to declare. Authors' contributions:S.M. drafting of the manuscript; D.E.C. critical revision of the manuscript for important intellectual content, obtained funding. Financial support:NIH R01 DK048872; R01 DK056626; R01 DK103046; R01 DK133988
-
Beyond Portal Hypertension: Characterizing Porto-Sinusoidal Vascular Disorder in Patients without signs of PH J. Hepatol. (IF 26.8) Pub Date : 2025-01-30 Nicola Pugliese, Stella De Nicola, Luca di Tommaso, Alessio Aghemo
Section snippets Authors' contributionsConceptualization, N.P. A.A. and S.D.N.; Investigation, N.P. and L.D.T.; Writing – Original Draft Preparation, N.P. and S.D.N.; Writing – Review & Editing, A.A.; Supervision, A.A.. Data availability statement (delete if not applicable)The data that support the findings of this study are available from the corresponding author, [author initials], upon reasonable
-
HEPATIC NODULE AND RISING AFP LEVELS: COULD IT INDICATE A BENIGN CONDITION? J. Hepatol. (IF 26.8) Pub Date : 2025-01-29 Veronique Vitton, L’Houcine Ouafik, Karine Nguyen
Section snippets Authors' contributionsVeronique Vitton: analyzed the whole clinical case and data and wrote the articleL’houcine Ouafik: analyzed all the laboratories data and wrote the articleKarine NGuyen: studied the genetic profile and wrote the articleCaroline Prost: made all the imaging tests and provides the figures and figures legendsBrigitte Granel: analyzed the whole clinical case and data
-
Response letter ‘Plasma exchange does not improve overall survival in patients with acute liver failure in a real world cohort’ J. Hepatol. (IF 26.8) Pub Date : 2025-01-29 Laura Burke, Ian Rowe, Mansoor Nawaz Bangash, Rajiv Jalan, Joanna Moore
Section snippets Authors contributionsAll authors contributed to drafting and review of the response. Role of the Funding sourceThere was no funding source for the study Declaration of Competing InterestRJ: has research collaborations with Yaqrit and Takeda. He is the inventor of OPA which has been patented by University College London and licensed to Mallinckrodt Pharma. He is also a founder of Yaqrit
-
Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia J. Hepatol. (IF 26.8) Pub Date : 2025-01-29 Iiris Nyholm, Maria Hukkinen, Jouko Lohi, Nelli Sjöblom, Aino Mutka, Annika Mutanen, Satu Ruuska, Mikko Neuvonen, Satu Hänninen, Olli Carpén, Johanna Arola, Timo Jahnukainen, Mikko Niemi, Markku Heikinheimo, Mikko P. Pakarinen
-
Increased HBsAg loss in HBeAg-negative patients with chronic hepatitis B and concurrent MASLD J. Hepatol. (IF 26.8) Pub Date : 2025-01-29 Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Chao Wu, Rui Huang
Section snippets Data availability statement (delete if not applicable)Due to the privacy protection, the dataset used in this study is available from the corresponding author upon reasonable request. Authors' contributionsDr. Huang had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Concept and design: Huang, Wang
-
Update in clinical science: Autoimmune hepatitis J. Hepatol. (IF 26.8) Pub Date : 2025-01-27 Michael A. Heneghan, Ansgar Wilhelm Lohse
Autoimmune hepatitis (AIH) is an enigmatic, relatively rare disease with a variable spectrum of presentation whose pathogenesis, diagnosis and management remain a major challenge. We have performed a review of recent developments in basic science, epidemiology, clinical science, therapeutics, and regulatory science, evaluating the challenges associated with the application of translational research
-
Qualitative study explores patient preferences for Metabolic dysfunction Associated Steatotic Liver Disease nomenclature J. Hepatol. (IF 26.8) Pub Date : 2025-01-23 Katie Williams, Daniel J. Cuthbertson, Louise Roper, Ian Rowe, Theresa J. Hydes
Section snippets Data availability statement (delete if not applicable)Data is available within the main article or its supplementary materials. Authors' contributionsKW interviews, thematic analysis and writing; DC critical revision; LR interviews and thematic analysis, critical revision; TH concept and writing; IR concept and critical revision. Financial supportAcademy of Medical Sciences Starter
-
Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries? J. Hepatol. (IF 26.8) Pub Date : 2025-01-23 Ajay kumar Mishra
Section snippets Uncited reference1.; 5.; 1.; 5.. Authors' contributionsWritten by Ajay kumar Mishra Financial supportNone Declaration of Competing InterestNonePlease refer to the accompanying ICMJE disclosure forms for further details. AcknowledgementsNone
-
Reply to “Plasma metabolomics promises to facilitate precise prevention of MASH and mortality from liver disease” J. Hepatol. (IF 26.8) Pub Date : 2025-01-23 Qingxia Huang, Huiru Tang, Xin Gao, Mingfeng Xia
Section snippets Uncited reference[4]; [4]. Authors' contributionsAll authors contributed to the drafting and revision of this letter. Financial supportWe acknowledge financial support from the National Key Research and Development Program of China (2021YFC2700403, 2022YFC3400700, 2022YFA0806400), the Shanghai Municipal Science and Technology Major Project (2023SHZDZX02), the Science and Technology
-
Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis J. Hepatol. (IF 26.8) Pub Date : 2025-01-22 Sitong Zhu, Lei Liao, Yi Zhong, Zhenming Liu, Junfeng Lu, Zhiwei Yang, Yibei Xiao, Xiaojun Xu
-
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease J. Hepatol. (IF 26.8) Pub Date : 2025-01-23 Terry Cheuk-Fung Yip, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N. Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Grazia
-
Radiation Segmentectomy for Early Hepatocellular Carcinoma is Curative J. Hepatol. (IF 26.8) Pub Date : 2025-01-22 Riad Salem, Siddharth A. Padia, Beau B. Toskich, Jon D. Callahan, Kirk D. Fowers, Brian S. Geller, Guy E. Johnson, Laura Kulik, Tushar C. Patel, Robert J. Lewandowski, Edward Kim
In this Expert Opinion, we provide the rationale for concluding that radiation segmentectomy (using RADSEG method), a technique of administrating ablative, complete necrosis-inducing trans-arterial Yttrium-90 (Y90) radiotherapy in limited-disease burden hepatocellular carcinoma (HCC), is curative. Currently, curative options for early stage and other carefully selected HCC patients include transplantation
-
Tertiary lymphoid structure dynamics at the centre of immunotherapy response in hepatocellular carcinoma J. Hepatol. (IF 26.8) Pub Date : 2025-01-21 David J. Pinato
Section snippets Background and contextMost patients with hepatocellular carcinoma (HCC) present with unresectable or advanced disease, where there is currently no hope for a cure. Only a minority of patients who present today with early-stage HCC can be cured following liver resection or transplantation. Post-operative relapse can affect up to 70% of patients who undergo curative resection and although
-
GRINA alleviates hepatic ischemia‒reperfusion injury-induced apoptosis and ER-phagy by enhancing HRD1-mediated ATF6 ubiquitination J. Hepatol. (IF 26.8) Pub Date : 2025-01-22 Hongjun Yu, Chaoqun Wang, Baolin Qian, Bing Yin, Shanjia Ke, Miaoyu Bai, Shounan Lu, Yanan Xu, Zhigang Feng, Zihao Li, Xinglong Li, Yongliang Hua, Zhongyu Li, Dong Chen, Yongzhi Zhou, Zhanzhi Meng, Yao Fu, Yong Ma
-
Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions J. Hepatol. (IF 26.8) Pub Date : 2025-01-21 Wenzhen Ding, Yaqing Meng, Jun Ma, Chuan Pang, Jiapeng Wu, Jie Tian, Jie Yu, Ping Liang, Kun Wang
-
Antiviral treatment of chronic hepatitis D virus infection: To combine or not to combine? J. Hepatol. (IF 26.8) Pub Date : 2025-01-20 Lisa Sandmann
Section snippets Background and contextThe treatment landscape of chronic hepatitis D (CHD) has changed significantly with the approval of the first approved anti-HDV drug, the entry inhibitor bulevirtide (BLV). By blocking the NTCP receptor, BLV inhibits the entry of HBsAg-coated viral particles into hepatocytes, thus preventing receptor-mediated infection of previously uninfected cells. With ongoing
-
On the need for an adult-to-adult liver graft split policy-An appraisal J. Hepatol. (IF 26.8) Pub Date : 2025-01-18 Xavier Muller, Guillaume Rossignol, Corinne Antoine, Kayvan Mohkam, Jean-Yves Mabrut
Section snippets Data availability statement (delete if not applicable)The data can be obtained upon reasonable request from the corresponding author. AcknowledgementsWe thank the entire team form the Agence de la Biomédecine for providing data on split liver transplantation in France. Authors' contributionsXM, GR, KM and JYM designed the study, CA provided data for the study, XM drafted a first version
-
Genomic and transcriptomic signatures of sequential carcinogenesis from papillary neoplasm to biliary tract cancer J. Hepatol. (IF 26.8) Pub Date : 2025-01-18 Taek Chung, Seungho Oh, Jeongsoo Won, Jiho Park, Jeong Eun Yoo, Ho Kyoung Hwang, Gi Hong Choi, Chang Moo Kang, Dai Hoon Han, Sangwoo Kim, Young Nyun Park
-
Modeling the Health and Economic Impact of Pharmacologic Therapies for MASLD in the United States J. Hepatol. (IF 26.8) Pub Date : 2025-01-18 Carolyn Wallace, Ivane Gamkrelidze, Chris Estes, Homie Razavi, Arun J. Sanyal
-
Reading through circular RNAs in MASLD: new diagnostic and therapeutic opportunities may come around J. Hepatol. (IF 26.8) Pub Date : 2025-01-17 Maite G. Fernandez-Barrena, Matias A. Avila
Section snippets FundingWork in the authors’ laboratory is funded by: Grant PID2022-136616OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by FEDER UE and PID2020-120387RB-I00 funded by MCIN/AEI/10.13039/501100011033; grant ERA-NET TRANSCAN-3 TRANSCAN2022-784-024; grant from Scientific Foundation of the Spanish Association Against Cancer (AECC) LABAE20011GARC. M.G.F.-B receives a Ramón y Cajal Program
-
The Journal of Hepatology: A new team at 40 J. Hepatol. (IF 26.8) Pub Date : 2025-01-16 Vlad Ratziu, Frank Tacke
Section snippets Financial supportThe authors did not receive any financial support to produce this manuscript. Conflict of interestThe authors of this study declare that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.
-
Zonal control of liver inflammation is orchestrated by periportal kupffer cells J. Hepatol. (IF 26.8) Pub Date : 2025-01-16 Prakash Ramachandran
Section snippets Background and contextZonation of the liver along the porto-central axis has long been described, but the advent of high-resolution omics technologies has transformed our understanding of the molecular drivers of zonation. Indeed, the impact of zonation on the function of hepatocytes, sinusoidal endothelial cells and hepatic stellate cells has been well described in recent years. The
-
-
EASL Congress 2025: prepare and submit your late-breaker! J. Hepatol. (IF 26.8) Pub Date : 2025-01-15
No Abstract
-
Register now for the EASL SLD Summit 2025, 23-25 January in Estoril J. Hepatol. (IF 26.8) Pub Date : 2025-01-15
No Abstract
-
Join the community and become an EASL member today! J. Hepatol. (IF 26.8) Pub Date : 2025-01-15
No Abstract
-
-
-
From the Editor’s Desk... J. Hepatol. (IF 26.8) Pub Date : 2025-01-15 Philip Newsome, Frank Tacke, Heiner Wedemeyer, Lorenza Rimassa, Annalisa Berzigotti, Tom H. Karlsen, Vlad Ratziu
Section snippets Peg-IFNα reduces relapse in HBeAg-negative patients after NA cessationThis issue included two interesting manuscripts which could imply new indications for Peg-IFNα for the personalised management of hepatitis B. Li, Qiu, Liu and coworkers performed a randomised-controlled trial to explore if Peg-IFNα could reduce post-treatment relapse after stopping nucleo(s)tide analogues (NAs)
-
-
Introducing the Breakthrough Beyond the Journal series J. Hepatol. (IF 26.8) Pub Date : 2025-01-15 Vlad Ratziu
No Abstract
-
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD J. Hepatol. (IF 26.8) Pub Date : 2025-01-15 Diana Barb MD, Srilaxmi Kalavalapalli PhD, Eddison Godinez Leiva MD, Fernando Bril MD, Philippe Huot-Marchand, Lucile Dzen, Jens T. Rosenberg PhD, Jean-Louis Junien, Pierre Broqua, Andrea Ortiz Rocha MD, Romina Lomonaco MD, Jean-Louis Abitbol, Michael P. Cooreman MD, Kenneth Cusi MD
-
Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges J. Hepatol. (IF 26.8) Pub Date : 2025-01-14 Anne Geng, Robert G. Brenig, Julien Roux, Mechthild Lütge, Hung-Wei Cheng, Emilio E. Flint, Paul O.G. Lussier, Marie-Anne Meier, Oltin T. Pop, Patrizia Künzler-Heule, Matthias S. Matter, Julia Wendon, Mark J.W. McPhail, Savas Soysal, David Semela, Markus Heim, Chris J. Weston, Burkhard Ludewig, Christine Bernsmeier
-
Procedural bleeding in patients with cirrhosis: from prediction towards prevention J. Hepatol. (IF 26.8) Pub Date : 2025-01-11 Ton Lisman
Section snippets Authors' contributionsTL wrote the letter Financial supportNone Declaration of Competing InterestNonePlease refer to the accompanying ICMJE disclosure forms for further details. AcknowledgementsN/A
-
Social Work in Emergency Management: Strengthening Prevention Networks and Support Systems for Global Liver Cancer Control J. Hepatol. (IF 26.8) Pub Date : 2025-01-11 Haoyu Liu
Section snippets Authors contributionsHaoyu LIU: Methodology, Formal analysis, Writing - Original Draft, Conceptualization, Methodology, Supervision, Writing - Review & Editing. Financial support statementNo fundings were received for this research. Declaration of Competing InterestThe authors declare no conflicts of interest that pertain to this work.
-
Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy? J. Hepatol. (IF 26.8) Pub Date : 2025-01-11 Marika Rudler
Section snippets Background and contextIn cirrhosis, prognosis is mainly determined by the development of portal hypertension-related complications. Among them, acute variceal bleeding (AVB) remains associated with a mortality rate as high as 15-20%,1 depending on the severity of portal hypertension, liver function impairment, overt hepatic encephalopathy and hepatocellular carcinoma.2 Historically
-
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial J. Hepatol. (IF 26.8) Pub Date : 2025-01-10 Jasmohan S. Bajaj, Andrew Fagan, Edith A. Gavis, Richard K. Sterling, Mary Leslie Gallagher, Hannah Lee, Scott C. Matherly, Mohammed S. Siddiqui, Amy Bartels, Travis Mousel, Brian C. Davis, Puneet Puri, Michael Fuchs, Daphne M. Moutsoglou, Leroy R. Thacker, Masoumeh Sikaroodi, Patrick M. Gillevet, Alexander Khoruts
-
Cellular interactions in self-directed immune mediated liver diseases J. Hepatol. (IF 26.8) Pub Date : 2025-01-08 Amber G. Bozward, Scott P. Davies, Sean M. Morris, Kayani Kayani, Ye H. Oo
The lymphocyte population must traverse a complex path throughout their journey to the liver. The signals which these cells must detect, including cytokines, chemokines and other soluble factors, steer their course towards further crosstalk with other hepatic immune cells, hepatocytes and biliary epithelial cells. A series of specific chemokine receptors and adhesion molecules drive not only the recruitment
-
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials J. Hepatol. (IF 26.8) Pub Date : 2025-01-09 Javier Armisen, Mitra Rauschecker, Janeli Sarv, Mathias Liljeblad, Linda Wernevik, Mohammad Niazi, Jane Knöchel, Olof Eklund, Therése Sandell, James Sherwood, Linnéa Bergenholm, Stefan Hallén, Shan Wang, Prasad Kamble, Maria Bhat, Ingela Maxvall, Yixin Wang, Richard G. Lee, Sanjay Bhanot, Shuling Guo, Stefano Romeo, Eric Lawitz, Ola Fjellström, Daniel Lindén, Jenny E. Blau, Rohit Loomba